Skip to content

Treatment strategy in patients with recurrent vasovagal syncope.

Treatment strategy in patients with recurrent vasovagal syncope.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28970
Enrollment
300
Registered
2005-08-24
Start date
2005-01-02
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vasovagal syncope

Interventions

1. Physical Counterpressure Manoeuvres
2. Midodrine.

Sponsors

Academic Medical Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinical diagnosis of classical neurally- mediated reflex syncope, based on the medical history ór non-classical diagnosis of neurally-mediated reflex syncope and a positive tilt-table test; 2. 3 syncope episodes in the last 2 years; 3. Recognizable prodromal symptoms; 4. Age 18-70 years.

Exclusion criteria

Exclusion criteria: 1. Suspected or certain heart disease and high likelihood of cardiac syncope; 2. Orthostatic hypotension; 3. Episodes of loss of consciousness different from syncope (e.g. epilepsy, psychiatric, metabolic, drop-attack, TIA, intoxication, cataplexy); 4. Steal syndrome; 5. Psychologically or physically (due to any other illness) or cognitively unfit for participation in the study according to the opinion of the investigator; 6. Patient compliance doubtful; 7. Patient geographically or otherwise inaccessible for follow-up; 8. Patient unwilling or unable to give informed consent; 9. Pregnancy; 10. Life expectancy < 1 year.

Design outcomes

Primary

MeasureTime frame
Total burden of syncope recurrence.

Secondary

MeasureTime frame
1. Time to first recurrence syncope and presyncope; 2. Presyncope burden; 3. Quality of life.

Contacts

Public ContactW. Wieling

Academic Medical Center (AMC), Department of Internal Medicine, P.O. Box 22660

w.wieling@amc.uva.nl+31 (0)20 5669111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)